

AMENDMENTS TO THE CLAIMS

Amendments to the claims are reflected in the following listing of claims, which replaces all prior versions or listings of claims.

1. (Currently amended) An isolated peptide ~~with an amino acid sequence consisting of 8-40 amino acids and~~ comprising the amino acid sequence set forth in any one of SEQ ID NOs: 35-66, wherein the peptide is 6-40 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).

2. (Previously presented) The isolated peptide according to claim 1, wherein the peptide comprises amino- and carboxy-terminal cysteine residues.

3.-11. (Cancelled)

12. (Previously presented) The isolated peptide according to claim 1, comprising the amino acid sequence set forth in any one of SEQ ID NOs: 35-43 and 55-66.

13. (Original) The isolated peptide of claim 1, wherein said peptide comprises the sequence CGYWLTIWGC (SEQ ID NO: 35).

14.-76. (Cancelled)

77. (Currently amended) The peptide of claim 12 or claim 13 ~~with an amino acid sequence consisting of~~ that is 10-25 amino acids in length.

78. (Currently amended) An isolated peptide ~~with an amino acid sequence consisting of 8-40 amino acids and~~ comprising the amino acid sequence set forth in SEQ ID

NO: 34, wherein the peptide is 8 to 40 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).

79. (Previously presented) The isolated peptide according to claim 78, wherein the peptide comprises amino- and carboxy-terminal cysteine residues.

80. (Currently amended) The isolated peptide of claim 78 ~~with an amino acid sequence consisting of~~ that is 8-35 amino acids in length.

81. (Currently amended) The isolated peptide of claim 80 ~~with an amino acid sequence consisting of~~ that is 10-30 amino acids in length.

82. (Currently amended) An isolated peptide ~~with an amino acid sequence consisting of 8-40 amino acids and~~ comprising the amino acid sequence spanning amino acid residue 2 through amino acid residue 9 of any one of SEQ ID NOs: 35 and 55-58, wherein the peptide is 8 to 40 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).

83. (Previously presented) The isolated peptide according to claim 82, wherein the peptide comprises amino- and carboxy-terminal cysteine residues.

84. (Currently amended) The isolated peptide of claim 82 ~~with an amino acid sequence consisting of~~ that is 8-35 amino acids in length.

85. (Currently amended) The isolated peptide of claim 84 ~~with an amino acid sequence consisting of~~ that is 10-30 amino acids in length.

86. (New) The isolated peptide according to claim 1, 78, or 82, wherein said peptide further comprises an intramolecular bond between amino acid residues to form a cyclic peptide.

87. (New) The isolated peptide according to claim 86, wherein the peptide comprises amino- and carboxy-terminal cysteines, and the intramolecular bond comprises a disulfide bond between the cysteines.

88. (New) The isolated peptide according to claim 1, 78, or 82, wherein said peptide inhibits Vascular Endothelial Growth Factor C (VEGF-C) binding to the human VEGFR-3.

89. (New) The isolated peptide according to claim 1, 78, or 82, further comprising a cytotoxic agent or a label attached to the peptide.

90. (New) The peptide of claim 89, wherein the label is attached to the peptide, said label selected from the group consisting of a radionuclide, a dye, an enzyme, and an enzyme substrate.

91. (New) The peptide according to claim 89, wherein the cytotoxic agent is attached to the peptide, said cytotoxic agent comprising a radioisotope.

92. (New) The peptide according to claim 89, wherein the cytotoxic agent is attached to the peptide, said cytotoxic agent comprising an anti-neoplastic pro-drug.

93. (New) A chimeric protein comprising a therapeutic protein amino acid sequence attached to the amino acid sequence of a peptide according to claim 1, 78, or 82.

94. (New) The chimeric protein according to claim 93, wherein the therapeutic protein comprises a tumor necrosis factor.
95. (New) The peptide according to claim 1, 78, or 82 attached to an antibody or fragment thereof.
96. (New) The isolated peptide of claim 1, 78, or 82, wherein said peptide further comprises a modification to increase the circulating *in-vivo* half-life of the peptide in a mammal.
97. (New) A peptide dimer comprising first and second peptides according to claim 1, 78, or 82.
98. (New) The peptide dimer according to claim 97, wherein the first and second peptides comprise the same amino acid sequence.
99. (New) A composition comprising an isolated peptide according to claim 1, 78, or 82 in a pharmaceutically acceptable carrier.
100. (New) The peptide of claim 1, 78, or 82, wherein the peptide is 8-25 amino acids in length.